KYMERA THERAPEUTICS, INC. Revenue, Remaining Performance Obligation, Amount
KYMERA THERAPEUTICS, INC. (KYMR) had Revenue, Remaining Performance Obligation, Amount of $51.40 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:RevenueRemainingPerformanceObligation · last filed 2025-02-27
- 2024-12-31: Revenue, Remaining Performance Obligation, Amount $51.40M.
- 2024-09-30: Revenue, Remaining Performance Obligation, Amount $49.70M.
- 2024-06-30: Revenue, Remaining Performance Obligation, Amount $49.10M.
- 2024-03-31: Revenue, Remaining Performance Obligation, Amount $42.60M.
| Period end | Revenue, Remaining Performance Obligation, Amount |
|---|---|
| 2024-12-31 | $51.40M 10-K · filed 2025-02-27 |
| 2024-09-30 | $49.70M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $49.10M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $42.60M 10-Q · filed 2024-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |